Chengdu Maxvax Biotechnology LLC (Maxvax) announced the completion of a 200-million-yuan convertible bond financing on the day following New Year’s Day, with investment from Shenzhen Capital Group’s (SCGC) National New Materials Fund for Manufacturing Transformation and Upgrading.

The funds raised through the convertible bond will be used to support the ongoing research and development of Maxvax’s innovative adjuvant platform and the expansion of production capacity for its new adjuvant workshop. Additionally, the funds will support Phase III clinical trials for the recombinant herpes zoster vaccine, Phase II and III clinical trials for the recombinant respiratory syncytial virus vaccine, as well as preclinical development and international collaborations for multiple innovative vaccine pipelines.

Maxvax is a high-tech enterprise focused on the research, development, production, and commercialization of innovative vaccines and new adjuvants. The company is dedicated to overcoming critical technological challenges in the vaccine field and has achieved significant advancements in the development of new adjuvants. Maxvax has independently developed more than 20 types of adjuvant raw materials, created three mature delivery systems, and developed over 10 types of composite formulations. The company has established a vertically integrated industrial chain, spanning from adjuvant raw material R&D and production to adjuvant formulation development and application. Maxvax also boasts a robust pipeline of major innovative vaccine candidates, built upon its leading novel adjuvants, recombinant protein platforms, and immunity evaluation platforms.

SCGC, established in 1999 during the first Hi-Tech Fair, is a leading investment group in China with a core focus on venture capital (VC) and private equity (PE). With the mission of “Discovering and Achieving Great Enterprises,” SCGC has been committed to being the discoverer and cultivator of innovative values. The group has built a diverse fund matrix that covers the entire life cycle of enterprises, with a total AUM of 480 billion yuan. Its New Material Fund for Manufacturing Transformation and Upgrading is a designated investment sector of the country’s National Fund for Manufacturing Transformation and Upgrading, primarily focusing on investments in the field of new materials.